Compare AstraZeneca plc (AZN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ABRDN Physical Gold Shares ETF — how do they compare? AstraZeneca plc trades at $168.59 (market cap $253.13B), while ABRDN Physical Gold Shares ETF trades at $38.65. The key difference: AstraZeneca plc pays a 1.92% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals.
| AZN | SGOL | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $51.41 |
52-Week Low | $137.44 | $31.18 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SGOL is trading at $38.1, down 2.61% amid broader gold market weakness. The technical picture shows bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. Gold ETFs face headwinds from rising Treasury yields and Federal Reserve policy uncertainty, though central bank buying provides underlying support. Recent CPI data provided temporary relief but failed to sustain momentum.
The outlook remains cautious as gold faces competing forces - supportive central bank demand versus restrictive monetary policy. Near-term direction hinges on Fed policy clarity and inflation trends, with technical resistance at $39-$40 levels posing immediate challenges for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
